Efficacy of Adjuvant Immunochemotherapy with Polysaccharide K for Patients with Curative Resections of Gastric Cancer

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2006 Nov 16

PMID 17106715

Citations 34

Authors

Koji Oba

Satoshi Teramukai

Michiya Kobayashi

Takanori Matsui

Yasuhiro Kodera

Junichi Sakamoto

Affiliations

Soon will be listed here.

Abstract

Non-specific immunopotentiators, such as polysaccharide K (PSK), also known as OK-432, induce anti-tumor effects via immunological responses. The efficacy of combination immunochemotherapy using these immunopotentiators has been examined by multiple previous studies. The survival benefits of immunochemotherapy for patients with curative resections of gastric cancers are not widely accepted. To clarify this issue, we performed a meta-analysis to evaluate the effect of immunochemotherapy on survival in patients with curative resections of gastric cancer. For this study, we compared the results of chemotherapy and immunotherapy using the biological response modifier PSK as an immunopotentiator. The meta-analysis included 8,009 patients from eight randomized controlled trials after central randomization. The overall hazard ratio for eligible patients was 0.88 (95% confidence interval, 0.79-0.98; P = 0.018) with no significant heterogeneity [chi (2)(8) for heterogeneity = 11.7; P = 0.16]. The results of this meta-analysis suggest that adjuvant immunochemotherapy with PSK improves the survival of patients after curative gastric cancer resection.

Citing Articles

Identification and Analysis of Anticancer Therapeutic Targets from the Polysaccharide Krestin (PSK) and Polysaccharopeptide (PSP) Using Inverse Docking.

Lopez-Gil C, Tellez-Jurado A, Velasco-Velazquez M, Anducho-Reyes M Molecules. 2024; 29(22).

PMID: 39598781 PMC: 11596896. DOI: 10.3390/molecules29225390.

β-glucan: a potent adjuvant in immunotherapy for digestive tract tumors.

Wang M, Pan J, Xiang W, You Z, Zhang Y, Wang J Front Immunol. 2024; 15:1424261.

PMID: 39100668 PMC: 11294916. DOI: 10.3389/fimmu.2024.1424261.

Advances and key focus areas in gastric cancer immunotherapy: A comprehensive scientometric and clinical trial review (1999-2023).

Li Y, Xie B, Zhang Y, He M, Xing Y, Mu D World J Gastroenterol. 2023; 29(40):5593-5617.

PMID: 37970478 PMC: 10642438. DOI: 10.3748/wjg.v29.i40.5593.

Research Progress on the Mechanisms of Polysaccharides against Gastric Cancer.

Chen L, He C, Zhou M, Long J, Li L Molecules. 2022; 27(18).

PMID: 36144560 PMC: 9501385. DOI: 10.3390/molecules27185828.

Immunomodulatory Effects of Edible and Medicinal Mushrooms and Their Bioactive Immunoregulatory Products.

Zhao S, Gao Q, Rong C, Wang S, Zhao Z, Liu Y J Fungi (Basel). 2020; 6(4).

PMID: 33171663 PMC: 7712035. DOI: 10.3390/jof6040269.

References

Maehara Y, Sugimachi K, Akagi M, Kakegawa T, Shimazu H, Tomita M . Early postoperative chemotherapy following noncurative resection for patients with advanced gastric cancer. Br J Cancer. 1992; 65(3):413-6. PMC: 1977594. DOI: 10.1038/bjc.1992.84. View

Nio Y, Tsubono M, Tseng C, Morimoto H, Kawabata K, Masai Y . Immunomodulation by orally administered protein-bound polysaccharide PSK in patients with gastrointestinal cancer. Biotherapy. 1992; 4(2):117-28. DOI: 10.1007/BF02171756. View

Kim R, Yoshida K, Toge T . Current status and future perspectives of post-operative adjuvant therapy for gastric carcinoma. Anticancer Res. 2002; 22(1A):283-9. View

Ochiai T, Sato H, Hayashi R, Asano T, Isono K, Suzuki T . Randomly controlled study of chemotherapy versus chemoimmunotherapy in postoperative gastric cancer patients. Cancer Res. 1983; 43(6):3001-7. View

Ichihashi H, Kondo T, Nakazato H . [Clinical results of a randomized controlled trial on the effect of adjuvant immunochemotherapy using Esquinon and Krestin in patients with curatively resected gastric cancer--7-year survival--Cooperative Study Group for Cancer Immunochemotherapy,...]. Gan To Kagaku Ryoho. 1987; 14(9):2758-66. View

Nakazato H, Ichihashi H, Kondo T . [Clinical results of a randomized controlled trial on the effect of adjuvant immunochemotherapy using Esquinon and Krestin in patients with curatively resected gastric cancer. Cooperative Study Group of Cancer Immunochemotherapy, Tokai...]. Gan To Kagaku Ryoho. 1986; 13(2):308-18. View

Nakazato H, Koike A, Ichihashi H, Saji S, Danno M, Ogawa N . [An effect of adjuvant immunochemotherapy using krestin and 5-FU on gastric cancer patients with radical surgery (first report)--a randomized controlled trial by the cooperative study group. Study Group of Immuno-chemotherapy with PSK for Gastric...]. Gan To Kagaku Ryoho. 1989; 16(8 Pt 1):2563-76. View

Ueda Y, Fujimura T, Kinami S, Hirono Y, Yamaguchi A, Naitoh H . A randomized phase III trial of postoperative adjuvant therapy with S-1 alone versus S-1 plus PSK for stage II/IIIA gastric cancer: Hokuriku-Kinki Immunochemo-Therapy Study Group-Gastric Cancer (HKIT-GC). Jpn J Clin Oncol. 2006; 36(8):519-22. DOI: 10.1093/jjco/hyl048. View

Nio Y, Tobe T . [Immunity of gut-associated lymphoid tissue and the role of the oral immunotherapy in multi-disciplinary treatment of the digestive organ cancer]. Nihon Geka Gakkai Zasshi. 1989; 90(9):1436-8. View

10.

Nakajima T, Inokuchi K, Hattori T, Inoue K, Taguchi T, Kondou T . [Multi-institutional cooperative study of adjuvant immunochemotherapy in gastric cancer--five-year survival rate]. Gan To Kagaku Ryoho. 1989; 16(4 Pt 1):799-806. View

11.

Parmar M, Torri V, Stewart L . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1999; 17(24):2815-34. DOI: 10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8. View

12.

Tanaka N, Aichi A, Nagata H, Funaki M, Okabayashi T, Hiden A . [Preoperative intra tumor biological response modifier injection therapy for patients with stomach neoplasms]. Nihon Rinsho Meneki Gakkai Kaishi. 1995; 18(6):626. View

13.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

14.

Akimoto M, Nishihira T, Kasai M . [Modulation of the anti-tumor effect of BRM under various nutritional or endocrine conditions]. Gan To Kagaku Ryoho. 1986; 13(4 Pt 2):1270-6. View

15.

Kondo M . Immunotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet. 1994; 344(8917):274. DOI: 10.1016/s0140-6736(94)93042-2. View

16.

Sastre J, Garcia-Saenz J, Diaz-Rubio E . Chemotherapy for gastric cancer. World J Gastroenterol. 2006; 12(2):204-13. PMC: 4066028. DOI: 10.3748/wjg.v12.i2.204. View

17.

Osawa S, Shiroto H, Kondo Y, Nakanishi Y, Fujisawa J, Miyakawa K . [Randomized controlled study on adjuvant immunochemotherapy with carmofur (HCFU) for noncuratively resected and unresected gastric cancer]. Gan To Kagaku Ryoho. 1996; 23(3):327-31. View

18.

Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J . Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet. 1994; 343(8906):1122-6. DOI: 10.1016/s0140-6736(94)90233-x. View

19.

Sakamoto J, Morita S, Oba K, Matsui T, Kobayashi M, Nakazato H . Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials. Cancer Immunol Immunother. 2005; 55(4):404-11. PMC: 11030578. DOI: 10.1007/s00262-005-0054-1. View

20.

Kobayashi H, Matsunaga K, Oguchi Y . Antimetastatic effects of PSK (Krestin), a protein-bound polysaccharide obtained from basidiomycetes: an overview. Cancer Epidemiol Biomarkers Prev. 1995; 4(3):275-81. View